<!DOCTYPE html>
<html lang="en">
    <head>
        <title>displaCy</title>
    </head>

    <body style="font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr">
<figure style="margin-bottom: 6rem">
<div class="entities" style="line-height: 2.5; direction: ltr"></br> ==== Front
 J EpidemiolJ EpidemiolJournal of Epidemiology0917-50401349-9092Elsevier S0917-5040(16)30081-810.1016/j.je.2016.12.006Original ArticleOverview of BioBank Japan follow-up data in 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Hirata Makoto aNagai Akiko bKamatani Yoichiro cNinomiya Toshiharu dTamakoshi Akiko eYamagata Zentaro fKubo Michiaki gMuto Kaori bKiyohara Yutaka hMushiroda Taisei iMurakami Yoshinori jYuji Koichiro kFurukawa Yoichi lZembutsu Hitoshi mnTanaka Toshihiro opqOhnishi Yozo orNakamura Yusuke msBioBank Japan Cooperative Hospital GroupShiono Masaki vMisumi Kazuo vKaieda Reiji vHarada Hiromasa vMinami Shiro wWatanabe Atsushi wEmoto Naoya wTakahashi Kazuhisa xTakeda Satoru xFunaki Toshinari xAsai Satoshi yMoriyama Mitsuhiko yTakahashi Yasuo yFujioka Tomoaki zObara Wataru zMori Seijiro aaIto Hideki aaNagayama Satoshi abMiki Yoshio abMasumoto Akihide acYamada Akira acNishizawa Yasuko adKodama Ken adKutsumi Hiromu aeSugimoto Yoshihisa aeKoretsune Yukihiro afKusuoka Hideo afYoshimori Kozo agv Tokushukai Hospitals, Japanw Nippon Medical School, Japanx Juntendo University, Japany Nihon University, Japanz Iwate Medical University, Japanaa Tokyo Metropolitan Institute of Gerontology, Japanab The Cancer Institute Hospital of 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    JFCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, Japanac Aso Iizuka Hospital, Japanad Osaka Medical Center for Cancer and Cardiovascular Diseases, Japanae Shiga University of Medical Science, Japanaf National Hospital Organization, Osaka National Hospital, Japanag Fukujuji Hospital, Japan uMatsuda Koichi kmatsuda@k.u-tokyo.ac.jpmt∗a Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japanb Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japanc Laboratory for Statistical Analysis, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RIKEN
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Center for Integrative Medical Sciences, Yokohama, Japand Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japane Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japanf Department of Health Sciences, University of Yamanashi, Yamanashi, Japang RIKEN Center for Integrative Medical Sciences, Yokohama, Japanh Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japani Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japanj Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japank Project Division of International Advanced Medical Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japanl Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japanm Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japann Division of Genetics, National Cancer Center Research Institute, Tokyo, Japano SNP Research Center, RIKEN Yokohama Institute, Yokohama, Japanp Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japanq Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japanr Shinko Clinic, Medical Corporation Shinkokai, Tokyo, Japans Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USAt Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan∗ Corresponding author. Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.Laboratory of Clinical Genome SequencingGraduate School of Frontier SciencesThe University of Tokyo4-6-1 ShirokanedaiMinato-kuTokyo108-8639Japan kmatsuda@k.u-tokyo.ac.jpu Hospital Group members are listed in Appendix A.
 
 10 2 2017 3 2017 10 2 2017 27 3 Suppl 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S22
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S28
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 22 10 2016 15 12 2016 © 2017 The 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Authors2017This
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 is an open access article under the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BY-NC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
-
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ND
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
 We established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. This follow-up survey focused on 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data.</br> </br> Methods</br> A total of 141,612 participants were included. The survival data were last updated in 2014. Kaplan–Meier survival analysis was performed after categorizing subjects according to sex, age group, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 status. Relative survival rates were estimated using a survival-rate table of the Japanese general population.</br> </br> Results</br> Of 141,612 subjects (56.48% male) with 1,087,434 person-years and a 97.0% follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 had the least favorable prognosis (10-year relative survival: 0.184) and patients with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 had the most favorable prognosis (1.013). The most common cause of death was 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. A number of subjects died from 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases other
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 than their registered disease(s).</br> </br> Conclusions</br> This is the first report to perform follow-up survival analysis across 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    various common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. Further studies should use detailed clinical and genomic information to identify predictors of mortality in patients with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, contributing to the implementation of personalized medicine.</br> </br> Highlights</br> • 141,612 participants with any of 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were included in the follow-up survey.</br> </br> • Subject characteristics at enrollment for the follow-up survey were identified.</br> </br> • The relative survival analysis showed the worst prognosis in 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> </br> • The most common cause of death in all subjects was 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> </br> </br> </br> Keywords</br> BioBank Japan projectBiobankCommon diseaseClinical informationFollow-up survey</br> ==== Body</br> Introduction</br> BioBank Japan (BBJ) was launched in 2003, establishing a large patient-oriented biobank in order to contribute to the implementation of personalized medicine. Approximately 200,000 patients diagnosed with any of 47 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    target common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were enrolled in the BBJ in the first 5-year period of the project.1, 2, 3 In this project, DNA, serum, and clinical information was collected from participants. This has been distributed to many researchers and companies, subject to an approved application, resulting in the publication of over 200 studies as of March 31 2016.4 Most studies have investigated genetic susceptibility to 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    various diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 or genetic factors affecting drug efficacy and susceptibility to adverse drug reactions, providing important medical information for the implementation of personalized medicine.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 However, to date, no study has investigated the genes or serum markers associated with long term prognosis, despite the fact that survival analysis is one of the most important aspects for the implementation of personalized medicine. Of the 47 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, we focused on 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, including 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, which are potentially associated with a poor vital prognosis. In 2010, we commenced the follow-up survival survey involving BBJ participants with any of the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 and updated the follow-up data until 2014. In the present study, we identified subject characteristics for the follow-up survey using clinical information at enrollment, performed survival analysis, and investigated the distribution of causes of death in the deceased subjects.</br> </br> Materials and methods</br> Study design</br> We enrolled patients with any one of the 47 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    target common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 between fiscal year of 2003 and 2007. For the follow-up survival survey, we focused on 32 out of the 47 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, associated with participant vital status (Table 1). Data collection was started in 2010. Details of the protocols, participant recruitment, collection of clinical information, and follow-up survey, were described elsewhere.2 Disease durations at the time of enrollment were calculated based on the date of onset or diagnosis of 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 and the date of enrollment for 25 out of the 32 diseases.2 The present protocols were reviewed and approved by the Ethics Committees of all participating institutions, including the Institute of Medical Science, the University of Tokyo, and the Center for Integrative Medical Sciences, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RIKEN
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. Written informed consent was obtained from all participants. Baseline clinical dataset after data-cleansing, and follow-up dataset updated in 2014, were used for the present study.</br> </br> Survival data analysis</br> We set the date of enrollment as a starting point for survival analysis. To examine whether the target 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 affected vital prognosis, relative survival rates were estimated as the ratio of the observed cumulative survival rates of subjects to the expected survival rates of a group of people of the corresponding sex and age in the general population. To calculate expected survival rates, a survival-rate table of general Japanese population was obtained from the Cancer Registry and Statistics, Cancer Information Service, National Cancer Center, Japan.21 The survival-rate table was based on sex- and age-specific mortality rates and Gompertz-Makeham's law in Abridged Life Tables, published annually by the Statistics and Information Department of the Ministry of Health, Labour and Welfare, Japan.22 Fifteen subjects ≥100 years old were excluded due to the lack of data in the general population life table. Information on the cause of death, according to the ICD-10 code, was collected for deceased subjects by matching birth date, date of death, sex, and local government code, with the Vital Statistics by the Statistics and Information Department of the Ministry of Health, Labour and Welfare, Japan.23 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SAS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 9.4 software were used for the data analysis. A p-value of &lt;0.05 was considered statistically significant.</br> </br> Results</br> Characteristics of the subjects in follow-up survey</br> Of 161,822 participants with any one of the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the BBJ cohort, 20,210 participants were excluded from this follow-up survey due to withdrawal of consent, withdrawal of hospitals, refusal of follow-up survey, and registration error of the target disease.2 A total of 141,612 (87.51%) were included in the follow-up survey. Among the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 was the most 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    common disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (n = 37,478), while gallbladder/cholangiocarcinoma were the least common (n = 366) (Table 1). Of all subjects, 56.48% were male and mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. Although the sex ratio varied among the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, there were no substantial differences of the mean age at enrollment between the sexes, according to 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. As all the participants were enrolled after onset or diagnosis of the target disease(s), we examined whether 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 durations at enrollment would affect participants' survivals. More than half of the subjects with 8 of the 13 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were enrolled within a year after diagnosis (eTable 1-1), while most of the subjects with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    other chronic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were enrolled more than 3 years (or even 5 years) after onset or diagnosis of the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (eTables 1-2 and 3), after excluding the subjects with unknown 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 durations.
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    
 
 Outlines of follow-up survival data
 Analysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 of follow-up data showed that median follow-up duration in all subjects was 8.40 years and follow-up rate was 97.0%. Of the 141,612 subjects with 1,087,434 person-years, 35,482 subjects died during follow-up. We could identify the causes of death in 31,054 (87.5%) cases. The follow-up rates across the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were comparable and even the lowest follow-up rate was 93.4% in drug eruption. In contrast, the median follow-up duration for each 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease varied
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 from 1.29 years for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 to 9.16 years for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebral aneurysm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, mostly dependent on the prognosis of each 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (Table 2). The 5-year and 10-year relative survival rates in all subjects were 0.944 and 0.911, respectively. The relative survival rates in each 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 showed that 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 exhibited the worst prognosis (0.291 over 5 years and 0.235 over 10 years), followed by other 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepato-biliary-pancreatic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 such as 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, gallbladder/cholangiocarcinoma, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver cirrhosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. Of note, the 10-year survival rates for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia and prostate cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were higher than those in the general population (10-year relative survival rate: 1.013 for both 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
) (Table 2). The observed survival analysis, stratified by 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 durations at enrollment revealed that 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 durations within one year were associated with low survival rates for most 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 except liver, prostate and breast 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. In contrast, longer 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 durations were associated with lower survival rates for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
: 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (eTable 1).</br> </br> Survival analysis with sex and age</br> Observed cumulative survival rates of all subjects, analyzed by Kaplan–Meier methods, showed improved prognosis in female subjects, while relative survival rates were similar between both sexes (Fig. 1A).</br> </br> Thirty-one of the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were categorized into seven groups: 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    locomotive disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (Table 1). Further survival analysis in each 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 category also found a poorer prognosis among male subjects, across all 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 categories (Fig. 2). Even in relative survival analysis, some 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 categories, such as 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    locomotive disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, exhibited a poorer prognosis among male subjects. Conversely, the relative survival rates in 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 showed a poorer prognosis among female subjects. Furthermore, the relative survival rates showed a rapid decline during the first four years but a slower decline at a later period for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, while 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    other diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 displayed a consistent decline throughout follow-up (Fig. 2). When the subjects were categorized according to their age groups, cumulative survival rates showed a clear trend of poorer prognosis with advancing age (Fig. 1B).
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    
 
 Analysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 of cause of death</br> The causes of death based on the ICD-10 code were also analyzed. The four most frequent underlying causes of death in Japan are 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (coded as C00-C97 by ICD-10), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 other than hypertension (I01-02, I05-09, I20-25, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    I30-I52
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    J12-J18
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
), and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (I60-69).23 Therefore, the underlying causes of death in the present analysis followed the same categorization. The order of frequency among all subjects according to the four cause-of-death categories was comparable with that in Vital Statistics, Japan, 2014 (Fig. 3). Analysis of the cause of death by 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 category revealed that the causes of death tended to be related to the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    registered disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
; 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 was the cause of death in 76.8% of subjects with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (42.9% of all subjects), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 was the cause of death in 27.6% of subjects with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (15.2% of all subjects), and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 was the cause of death in 17.1% of subjects with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (7.3% of all subjects) (Fig. 3).</br> </br> Discussion</br> In the present follow-up survey, 141,612 BioBank Japan participants with any of the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were included. Analysis of baseline clinical information of the subjects showed comparable characteristics (at least, according to sex and age) among all participants with the any one of the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (Table 1),3 even though a number of participants were excluded for various reasons.2 Of the 141,612 subjects with 1,087,434 person-years and 97.0% follow-up rate, 35,482 subjects died during the follow-up. The median follow-up duration was 8.40 years. Relative survival analysis revealed poor prognosis for some of the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 such as 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, and gallbladder/cholangiocarcinoma (Table 2), which had already been reported as lethal malignancies.24, 25, 26 Furthermore, two 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    other chronic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver cirrhosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    interstitial lung disease/lung fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, were also associated with a poor prognosis, with a 10-year-relative survival rate of less than 50%. Analysis of the causes of death showed that the four most frequent underlying causes of death in all the subjects were 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 other than hypertension, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> </br> To our knowledge, this is the first study to perform long-term follow-up survival surveys on 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    various common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, including 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    other chronic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. Analysis of relative survival rates according to sex showed that male subjects had a poorer prognosis for some 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 categories, such as 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    locomotive disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, while female subjects had a poorer prognosis for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. These results indicated that sex-linked factors may specifically affect survival in 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    such diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. Several earlier studies on 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 described relative survival rates after stratifying for some clinical variables, such as sex, presenting status, histological grade, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 stage. Further detailed survival analysis on 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 among the BBJ subjects with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 was also performed.27, 28, 29, 30, 31, 32 It is difficult to compare the results of relative survivals between the current and the previous studies, because of the different subject characteristics, such as ethnicity and life-style, and the differences in the health care system in other countries and the methods of enrollment used in Japan. The relative survival rates of 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the current study appeared higher than those in 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 statistics in Japan, published by the Foundation for Promotion of Cancer Research.33 This result is not surprising because a substantial proportion of 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 patients were registered more than one year after diagnosis, increasing the proportion of BBJ subjects with more favorable prognosis (eTable 1-1).</br> </br> Relative survival analysis also showed significantly better outcome in subjects with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 than in the general population (Table 2), even though the population should be unbiased representative, based on the national public database Vital Statistics. As 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 was expected to be associated with poor clinical outcome, as it is a major risk factor for atherosclerotic disease,34 further analysis is essential to identify the factors associated with a better prognosis in BBJ subjects with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> </br> The most frequent cause of death in the present study was 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, followed by 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (other than hypertension), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, which were also the four most frequent causes of death in the Vital Statistics (Fig. 3).23 However, a considerable number of subjects died from 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases other
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 than the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    registered diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. Indeed, as many participants were registered with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, we need to consider the effect or interaction of comorbidity. Further investigation using detailed clinical information, including comorbidity, may explain how registered disease(s) are associated with a cause of death.</br> </br> One of the limitations in the present study is the selection bias at the enrollment, as 12.5% of the BBJ participants with the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were excluded from the present study as they did not agree to the follow-up survey or for other reasons,2 and some of the subjects had been enrolled several years after diagnosis or onset of the disease(s). As it is generally challenging to set starting points for survival analysis follow-up in 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    chronic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, due to their ambiguous onset, in the present study, we set the starting point for follow-up at enrollment. However, we still need to consider the possibility that such selection bias interferes with the natural history of results. A further limitation is incomplete information relating to the cause of death. We could not identify the cause of death in approximately 12.5% of the deceased subjects because Vital Statics data of deceased individuals in 2014 was not available for this survey.</br> </br> In conclusion, a follow-up survey was performed for subjects with any one of the 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    target diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BBJ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Project. Characterization of the subjects enhanced the feasibility of the follow-up survey and survival analysis displayed different survival rates across the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
. Further studies, using detailed clinical and survival data, as well as genome-wide 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    single-nucleotide-polymorphism
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 data, already obtained from approximately 170,000 participants in BBJ,2, 3 may prompt us to identify precise predictors for mortality and allow for the implementation of personalized medicine.</br> </br> Conflicts of interest</br> None declared.</br> </br> Appendix A Author list for the BioBank Japan Cooperative Hospital Group
 Members of medical institutions cooperating on the BioBank Japan Project who coauthored this paper include Masaki Shiono, Kazuo Misumi, Reiji Kaieda, Hiromasa Harada (Tokushukai Hospitals); Shiro Minami, Atsushi Watanabe, Naoya Emoto (Nippon Medical School), Kazuhisa Takahashi, Satoru Takeda, Toshinari Funaki (Juntendo University), Satoshi Asai, Mitsuhiko Moriyama, Yasuo Takahashi (Nihon University), Tomoaki Fujioka, Wataru Obara (Iwate Medical University), Seijiro Mori, Hideki Ito (Tokyo Metropolitan Institute of Gerontology), Satoshi Nagayama, Yoshio Miki (The Cancer Institute Hospital of JFCR), Akihide Masumoto, Akira Yamada (Aso Iizuka Hospital), Yasuko Nishizawa, Ken Kodama (Osaka Medical Center for Cancer and Cardiovascular Diseases), Hiromu Kutsumi, Yoshihisa Sugimoto (Shiga University of Medical Science), Yukihiro Koretsune, Hideo Kusuoka (National Hospital Organization, Osaka National Hospital), and Kozo Yoshimori (Fukujuji Hospital).</br> </br> Appendix B Supplementary data</br> The following are the supplementary data related to this article: </br> </br> Acknowledgements</br> We express our gratitude to all the participants of the BioBank Japan Project. We thank all the medical coordinators of the cooperating hospitals for collecting samples and clinical information, as well as Yasushi Yamashita and staff members of the BioBank Japan Project for administrative support. We also thank Dr. Kumao Toyoshima for his overall supervision of the BioBank Japan Project. This study was supported by funding from the Tailor-Made Medical Treatment with the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BBJ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Project from Japan Agency for Medical Research and Development, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AMED
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (from April 2015), and the Ministry of Education, Culture, Sports, Science, and Technology (from April 2003 to March 2015).</br> </br> Peer review under the responsibility of The Japan Epidemiological Association.</br> </br> Appendix B Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.je.2016.12.006.</br> </br> Fig. 1 Survival curves of all subjects based on sex and age group classification. (A) Observed cumulative survival curves (solid) were analyzed by Kaplan–Meier methods. Relative survival rates (dotted) were estimated as the ratio of the observed cumulative survival rates of subjects to the expected survival rates, based on a survival-rate table of general Japanese population from the Cancer Registry and Statistics, Cancer Information Service, National Cancer Center, Japan. (B) Observed cumulative survival rates of all subjects by age-groups were analyzed by Kaplan–Meier methods. Categorization of age groups was performed according to age at enrollment.</br> </br> Fig. 1Fig. 2 Survival curves of patients by 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 group. Observed cumulative survival curves (solid) and relative survival rates (dotted) of male and female 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    BBJ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 patients for each 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 group: 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (A), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (B), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Respiratory disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (C), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (D), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cerebrovascular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (E), 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Metabolic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (F), and Locomotive 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (G). Observed cumulative survival curves were analyzed by Kaplan–Meier methods. Relative survival rates were estimated as the ratio of the observed cumulative survival rates of subjects to the expected survival rates.</br> </br> Fig. 2Fig. 3 Distribution of underlying cause of death in all subjects and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 categories. Each bar represents the distribution of underlying cause of death, categorized by 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICD10
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in all subjects or each 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 category; 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 were coded by C00-C97, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 (other than hypertension) 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    I01-I02
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, I05-I09, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    I20-I25
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, I27 and 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    I30-I52
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pneumonia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    J12-J18
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 I60-69. This categorization was based on Vital statistics (first from left), Japan in 2014, published by Ministry of Health Labour and Welfare, Japan.</br> </br> Fig. 3Table 1 Baseline characteristics of subjects with 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for follow-up survey.</br> </br> Table 1
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	32 diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	Number subjects	% of Male subjects	Mean age (y)	</br> Male subjects	Female subjects	</br> 	Whole cohort	141,612	56.48	64.24	63.98	</br> Mnb
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	Colorectal cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	6180	62.88	66.87	66.20	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Breast cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	5827	0.72	63.43	57.52
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Gastric cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	5734	73.60	66.84	64.83	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Prostate cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	4669	100.00	72.45	N/A
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Lung cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	3557	64.75	67.54	65.88	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Liver cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	1757	75.98	67.46	69.63	</br> Esophageal 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	1193	86.67	65.64	65.42	</br> Hematological 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	1182	53.98	60.44	60.00
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Uterine cervical cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	1123	0.00	N/A	51.65	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Uterine corpus cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	961	0.00	N/A	58.91
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Ovarian cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	816	0.00
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	N/A	56.31	
 Pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	382	64.66	65.86	65.99	</br> Gallbladder/cholangiocarcinoma	366	62.30	67.42	68.57	</br> Lvb	Chronic 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 C	5180	53.90	63.31	64.40	</br> Liver 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cirrhosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	2218	62.67	62.60	64.99	</br> Chronic 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 B	1179	62.60	54.45	55.19	</br> Crb	Cerebral infarction	13,955	63.55	68.46
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	70.90	
 Cerebral aneurysm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	2426	35.57	60.36	62.55	</br> Cvb	
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Arrhythmia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	14,184	65.01	66.82	68.78	</br> Stable angina	13,117	71.13	67.65	70.57	</br> Myocardial infarction	11,982	81.29	65.81	70.72	</br> Heart failure	6888	62.66	65.78	70.94	</br> Unstable angina	3944	74.62	66.62	71.08
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Peripheral arterial diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	2444	78.23	70.76	71.41	</br> Rsb	Bronchial 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	7380	49.30	52.24	53.20	</br> COPDa	2257	86.97	72.16	72.36
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Interstitial lung disease/Pulmonary fibrosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	749	58.21	68.53	67.54	</br> Mbb	Dyslipidemia	37,478	51.71	62.00	65.93	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Diabetes mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	34,523	64.03	63.13	65.39	</br> Lcb	Rheumatoid 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	3619	20.45	63.66	61.92	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Osteoporosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	5028	7.52	71.37	73.08	</br> Other	Drug eruption	527	46.11	60.29	54.67	</br> a 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> </br> b Left boxes indicate 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 categories for following analysis: Mn, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
; Lv, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
; Cr, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
; Cv, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
; Rs, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
; Mb, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
; Lc, 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    locomotive diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> </br> Table 2 Follow-up characteristics of subjects with any one of 32 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> </br> Table 232 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	Median follow-up duration (y)	Follow-up rate (%)	Observed survival rate (95% 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CI
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
)	Relative survival rate (95% 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CI)a
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	</br> 5-yearb	10-yearb	5-yearb	10-yearb	</br> Whole cohort	8.40	97.0	0.855 (0.853–0.857)	0.719 (0.716–0.721)	0.944 (0.942–0.946)	0.911 (0.907–0.914)	</br> Colorectal 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	7.95	97.7	0.759 (0.748–0.770)	0.625 (0.611–0.638)	0.849 (0.837–0.861)	0.816 (0.798–0.833)	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Breast cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.18	98.1	0.892 (0.883–0.899)	0.794 (0.782–0.806)	0.924 (0.915–0.931)	0.870 (0.857–0.883)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Gastric cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	7.90	97.4	0.743 (0.732–0.755)	0.598 (0.584–0.612)	0.837 (0.824–0.850)	0.796 (0.778–0.815)	</br> Prostate 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	7.83	97.8	0.802 (0.790–0.813)	0.609 (0.592–0.625)	0.987 (0.972–1.000)	1.013 (0.985–1.040)	</br> Lung 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	6.52	97.5	0.591 (0.574–0.607)	0.446 (0.428–0.465)	0.703 (0.683–0.722)	0.685 (0.657–0.714)	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Liver cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	3.31	96.2	0.398 (0.375–0.422)	0.188 (0.167–0.211)	0.448 (0.422–0.475)	0.251 (0.223–0.281)	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Esophageal cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	5.49	97.5	0.539 (0.509–0.567)	0.380 (0.348–0.412)	0.599 (0.565–0.630)	0.496 (0.454–0.538)	</br> Hematologic 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.03	98.3	0.787 (0.762–0.809)	0.632 (0.599–0.664)	0.850 (0.823–0.874)	0.760 (0.720–0.798)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Uterine cervical cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.97	96.3	0.890 (0.870–0.907)	0.839 (0.814–0.860)	0.912 (0.891–0.930)	0.889 (0.863–0.911)	</br> Uterine 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    corpus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.96	97.5	0.908 (0.887–0.924)	0.853 (0.827–0.876)	0.938 (0.917–0.955)	0.933 (0.904–0.958)	</br> Ovarian 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.52	97.9	0.771 (0.741–0.799)	0.685 (0.650–0.717)	0.792 (0.761–0.821)	0.733 (0.695–0.767)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	1.29	95.8	0.262 (0.218–0.308)	0.184 (0.144–0.228)	0.291 (0.242–0.342)	0.235 (0.184–0.292)	</br> Gallbladder/cholangiocarcinoma	2.36	97.5	0.406 (0.355–0.456)	0.292 (0.241–0.344)	0.455 (0.398–0.511)	0.384 (0.317–0.453)	</br> Chronic 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 C	7.90	96.0	0.782 (0.770–0.793)	0.608 (0.592–0.623)	0.852 (0.839–0.864)	0.751 (0.731–0.769)	</br> Liver 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cirrhosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	4.44	94.4	0.502 (0.481–0.523)	0.299 (0.278–0.321)	0.548 (0.525–0.571)	0.369 (0.343–0.396)	</br> Chronic 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 B	8.22	95.3	0.857 (0.835–0.876)	0.770 (0.741–0.796)	0.899 (0.876–0.919)	0.871 (0.838–0.900)	</br> Cerebral infarction	8.36	97.0	0.836 (0.829–0.842)	0.644 (0.635–0.653)	0.964 (0.956–0.971)	0.899 (0.887–0.912)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Cerebral aneurysm
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	9.16	98.2	0.931 (0.920–0.941)	0.834 (0.817–0.850)	0.988 (0.977–0.999)	0.965 (0.945–0.984)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Arrhythmia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.24	97.4	0.847 (0.841–0.853)	0.667 (0.658–0.676)	0.968 (0.961–0.975)	0.915 (0.903–0.928)	</br> Stable angina	8.54	97.5	0.864 (0.858–0.870)	0.703 (0.694–0.711)	0.988 (0.981–0.995)	0.967 (0.955–0.978)	</br> Myocardial infarction	8.55	97.3	0.849 (0.842–0.855)	0.677 (0.667–0.686)	0.963 (0.955–0.970)	0.909 (0.896–0.921)	</br> Heart failure	7.38	96.9	0.720 (0.709–0.731)	0.504 (0.489–0.518)	0.830 (0.817–0.842)	0.696 (0.675–0.715)	</br> Unstable angina	8.86	97.2	0.862 (0.850–0.872)	0.687 (0.671–0.703)	0.978 (0.964–0.989)	0.929 (0.907–0.951)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Peripheral arterial diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	6.94	96.8	0.700 (0.681–0.718)	0.443 (0.418–0.467)	0.832 (0.809–0.853)	0.668 (0.630–0.704)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Bronchial asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.74	94.8	0.923 (0.917–0.929)	0.829 (0.819–0.839)	0.986 (0.980–0.993)	0.972 (0.960–0.984)	</br> COPDc	6.89	96.1	0.664 (0.644–0.683)	0.403 (0.379–0.427)	0.812 (0.787–0.835)	0.655 (0.616–0.694)	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Interstitial lung disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	5.81	98.0	0.558 (0.522–0.593)	0.338 (0.298–0.379)	0.636 (0.595–0.677)	0.462 (0.407–0.518)	</br> Dyslipidemia	8.75	97.5	0.929 (0.927–0.932)	0.825 (0.820–0.829)	1.010 (1.008–1.013)	1.013 (1.007–1.018)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Diabetes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    mellitus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.44	96.9	0.861 (0.857–0.864)	0.710 (0.704–0.715)	0.944 (0.940–0.947)	0.887 (0.880–0.893)
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    	
 Rheumatoid arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.47	97.4	0.873 (0.861–0.883)	0.720 (0.702–0.736)	0.929 (0.916–0.939)	0.836 (0.816–0.855)	</br> 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Osteoporosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
	8.42	96.8	0.850 (0.839–0.859)	0.691 (0.676–0.706)	0.980 (0.967–0.990)	0.965 (0.944–0.986)	</br> Drug eruption	8.51	93.4	0.858 (0.824–0.886)	0.743 (0.698–0.783)	0.921 (0.885–0.951)	0.875 (0.822–0.922)	</br> a Relative survival rates were estimated as the ratio of the observed cumulative survival rates of subjects to the expected survival rates, based on abridged life tables from Ministry of Health, Labour and Welfare, Japan. Subjects ≥100 years old were excluded because of lack of data in the reference life tables.</br> </br> b Each period describes duration after registration.
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    
 
 c Chronic obstructive pulmonary disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
.</br> ==== Refs</br> References</br> 1 Nakamura Y.   The BioBank Japan project Clin Adv Hematol Oncol 5 2007 696 697 17982410 </br> 2 Nagai A.  Hirata M.  Kamatani Y.   Overview of the BioBank Japan project: study design and profile J Epidemiol 27 2017 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S8
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 28189464 </br> 3 Hirata M.  Kamatani Y.  Nagai A.   Cross-sectional analysis of BioBank Japan clinical data: a large cohort of 200,000 patients with 47 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 J Epidemiol 27 2017 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S9
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S21
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 28190657 </br> 4 BioBank Japan. Publications from BioBank Japan. https://biobankjp.org/work/public.html; Updated 30.06.16. Accessed 25 July 2016.</br> 5 Kubo M.   Recent advances in the genome-wide association study of 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    common diseases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Nihon Rinsho 68 Suppl 8 2010 129 133 (in Japanese) 20976894 </br> 6 Arakawa S.  Takahashi A.  Ashikawa K.   Genome-wide association study identifies two 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    susceptibility loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for exudative age-related macular degeneration in the Japanese population Nat Genet 43 2011 1001 1004 21909106 </br> 7 Hirota T.  Takahashi A.  Kubo M.   Genome-wide association study identifies three 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    new susceptibility loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adult asthma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the Japanese population Nat Genet 43 2011 893 896 21804548 </br> 8 Hirota T.  Takahashi A.  Kubo M.   Genome-wide association study identifies eight 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    new susceptibility loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    atopic dermatitis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the Japanese population Nat Genet 44 2012 1222 1226 23042114 </br> 9 Kou I.  Takahashi Y.  Johnson T.A.   Genetic variants in 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GPR126
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 are associated with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adolescent idiopathic scoliosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Nat Genet 45 2013 676 679 23666238 </br> 10 Kumar V.  Kato N.  Urabe Y.   Genome-wide association study identifies a 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    susceptibility locus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HCV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
-induced hepatocellular carcinoma Nat Genet 43 2011 455 458 21499248 </br> 11 Miki D.  Ochi H.  Hayes C.N.   Variation in the 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DEPDC5
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    locus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 is associated with progression to hepatocellular carcinoma in chronic 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis C virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 carriers Nat Genet 43 2011 797 800 21725309 </br> 12 Okada Y.  Kubo M.  Ohmiya H.   Common variants at CDKAL1 and KLF9 are associated with body mass index in East Asian populations Nat Genet 44 2012 302 306 22344221 </br> 13 Okada Y.  Momozawa Y.  Ashikawa K.   Construction of a population-specific HLA imputation reference panel and its application to Graves' 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 risk in Japanese Nat Genet 47 2015 798 802 26029868 </br> 14 Okada Y.  Sim X.  Go M.J.   Meta-analysis identifies 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    multiple loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 associated with kidney function-related traits in East Asian populations Nat Genet 44 2012 904 909 22797727 </br> 15 Okada Y.  Terao C.  Ikari K.   Meta-analysis identifies nine 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    new loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 associated with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rheumatoid arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the Japanese population Nat Genet 44 2012 511 516 22446963 </br> 16 Okamoto K.  Tokunaga K.  Doi K.   Common variation in GPC5 is associated with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    acquired nephrotic syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Nat Genet 43 2011 459 463 21441931 </br> 17 Onouchi Y.  Ozaki K.  Burns J.C.   A genome-wide association study identifies three 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    new risk loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for Kawasaki 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Nat Genet 44 2012 517 521 22446962 </br> 18 Shiraishi K.  Kunitoh H.  Daigo Y.   A genome-wide association study identifies two 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    new susceptibility loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for lung adenocarcinoma in the Japanese population Nat Genet 44 2012 900 903 22797724 </br> 19 Takahashi Y.  Kou I.  Takahashi A.   A genome-wide association study identifies common variants near LBX1 associated with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    adolescent idiopathic scoliosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 Nat Genet 43 2011 1237 1240 22019779 </br> 20 Tanikawa C.  Urabe Y.  Matsuo K.   A genome-wide association study identifies two 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    susceptibility loci
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 for duodenal ulcer in the Japanese population Nat Genet 44 430–434 2012 S1 S2 
 21 Cancer Registry and Statistics, Cancer Information Service, National Cancer Center. Cohort Life Table. http://ganjoho.jp/reg_stat/statistics/qa_words/cohort01.html (in Japanese); Updated 11.03.16. Accessed 28 March 2016.</br> 22 Ministry of Health, Labour and Welfare, Japan   Abridged Life Tables for Japan 2014 (in Japanese) http://www.mhlw.go.jp/toukei/saikin/hw/seimei/list54-57-02.html Accessed 28 March 2016 </br> 23 Ministry of Health, Labour and Welfare, Japan. Vital Statistics. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei14/dl/10_h6.pdf (in Japanese); Updated 01.06.15. Accessed 03 March 2016.</br> 24 Ansari D.  Tingstedt B.  Andersson B. 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
      Pancreatic cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
: yesterday, today and tomorrow Future Oncol 12 2016 1929 1946 27246628 </br> 25 Blechacz B.  Gores G.J.   Cholangiocarcinoma: advances in 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pathogenesis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
, diagnosis, and treatment Hepatology 48 2008 308 321 18536057 </br> 26 Wallace M.C.  Preen D.  Jeffrey G.P.  Adams L.A.   The evolving epidemiology of hepatocellular carcinoma: a global perspective Expert Rev Gastroenterol Hepatol 9 2015 765 779 25827821 </br> 27 Tamakoshi A.  Nakamura K.  Ukawa S.   Characteristics and prognosis of Japanese colorectal 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 patients: the BioBank Japan Project J Epidemiol 27 2017 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S36
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S42
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 28214186 </br> 28 Nakamura K.  Ukawa S.  Okada E.   Characteristics and prognosis of Japanese 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    male and female lung cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 patients: the BioBank Japan Project J Epidemiol 27 2017 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S49
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 S57 28202209 </br> 29 Nakamura K.  Okada E.  Ukawa S.   Characteristics and prognosis of Japanese 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    female breast cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 patients: the BioBank Japan Project J Epidemiol 27 2017 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S58
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S64
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 28223083 </br> 30 Ukawa S.  Nakamura K.  Okada E.   Characteristics of the patients with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the BioBank Japan Project J Epidemiol 27 2017 S43 S48 28214185 </br> 31 Ukawa S.  Nakamura K.  Okada E.   Clinical and histopathological characteristics of the patients with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    prostate cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 in the BioBank Japan Project J Epidemiol 27 2017 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S65
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 S70 28215481 </br> 32 Okada E.  Nakamura K.  Ukawa S.   Demographic and lifestyle factors and survival among patients with 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    esophageal and gastric cancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
: the BioBank Japan Project J Epidemiol 27 2017 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    S29
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 S35 28190659 
 33 Foundation for Promotion of Cancer Research, Japan   Cancer Statistics in Japan, 2015 2005 http://ganjoho.jp/en/professional/statistics/brochure/2015_en.html Accessed 20 June 2016 </br> 34 Anderson T.J.  Mancini G.B.  Genest J. Jr.  Gregoire J.  Lonn E.M.  Hegele R.A.   The new 
<mark class="entity" style="background: #909090; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyslipidemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">DIS</span>
</mark>
 guidelines: what is the debate? Can J Cardiol 31 2015 605 612 25816728</br> </br></div>
</figure>
</body>
</html>